Abstract:Background: Monoclonal antibodies (mAbs) as biopharmaceuticals take a pivotal role in the current therapeutic applications. Generally mammalian cell lines, such as those derived from Chinese hamster ovaries (CHO), are used to produce the recombinant antibody. However, there are still concerns about the high cost and the risk of pathogenic contamination when using mammalian cells. Aspergillus oryzae, a filamentous fungus recognized as a GRAS (Generally Regarded As Safe) organism, has an ability to secrete a large amount of proteins into the culture supernatant, and thus the fungus has been used as one of the cost-effective microbial hosts for heterologous protein production. Pursuing this strategy the human anti-TNFα antibody adalimumab, one of the world's best-selling antibodies for the treatment of immune-mediated inflammatory diseases including rheumatoid arthritis, was chosen to produce the full length of mAbs by A. oryzae. Generally, N-glycosylation of the antibody affects immune effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) via binding to the Fc receptor (FcγR) on immune cells. The CRISPR/Cas9 system was used to first delete the Aooch1 gene encoding a key enzyme for the hyper-mannosylation process in fungi to investigate the binding ability of antibody with FcγRIIIa. Results: Adalimumab was expressed in A. oryzae by the fusion protein system with α-amylase AmyB. The full-length adalimumab consisting of two heavy and two light chains was successfully produced in the culture supernatants. Among the producing strains, the highest amount of antibody was obtained from the ten-protease deletion strain (39.7 mg/L). Two-step purifications by Protein A and size-exclusion chromatography were applied to obtain the high purity sample for further analysis. The antigen-binding and TNFα neutralizing activities of the adalimumab produced by A. oryzae were comparable with those of a commercial product Humira®. No apparent binding with the FcγRIIIa was detected with the recombinant adalimumab even by altering the N-glycan structure using the Aooch1 deletion strain, which suggests only a little additional activity of immune effector functions. Conclusion: These results demonstrated an alternative low-cost platform for human antibody production by using A. oryzae, possibly offering a reasonable expenditure for patient's welfare.

Characterization and high‐yield production of non‐N‐glycosylated recombinant human BCMA‐Fc in Pichia pastoris

Expression, purification, and characterization of recombinant human soluble BAFF secreted from the yeast Pichia pastoris

Expression of mouse soluble B cell activating factor belonging to the TNF family in Pichia pastoris and purification and biological activity of expressed product

Generation of a fusion protein of the extracellular domain of BR3 with the Fc fragment of human IgG1 (sBR3-Fc) in Pichia pastoris as an antagonist for BLyS

Expression of tumor necrosis factor receptor-immunoglobulin G1 Fc fusion protein in glycoengineered Pichia pastoris

An Optimized Fermentation and Purification Process for a Recombinant Human Antibody ScFv-Fc Fragment Expressed in Pichia Pastoris

High Level Expression and Purification of Recombinant Human Serum Albumin in Pichia Pastoris.

Medium Optimization for High Yield Production of Human Serum Albumin in Pichia Pastoris and Its Efficient Purification

Purification and Characterization of Human Il-10/Fc Fusion Protein Expressed in Pichia Pastoris

An efficient constitutive expression system for Anti-CEACAM5 nanobody production in the yeast Pichia pastoris

Efficient Production of FAM19A4, a Novel Potential Cytokine, in a Stable Optimized CHO-S Cell System.

Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris

Expression,purification and bioactivity identification of recombinant human BAFF fusion protein

Production and Characterization of LEA29Y, a Variant of Cytotoxic T-lymphocyte Antigen 4-Immunoglobulin, in Pichia Pastoris.

High-level Expression of a Functional Humanized Anti-Ctla4 Single-Chain Variable Fragment Antibody in Pichia Pastoris.

Production of Recombinant Humanized Anti-Hbsag Fab Fragment from Pichia Pastoris by Fermentation.

Prokaryotic Expression of Ebcma-Fc Fusion Protein,a Soluble BLyS Receptor,with Computer-aided Molecular Design in E. Coli

Expression of an interleukin-6 - interleukin-2 fusion protein (pIL-6-IL-2) in P. pastoris

Production and Characterization of Human Soluble CD83 Fused with the Fragment Crystallizable Region of Human IgG1 in Pichia Pastoris

Functional production of human antibody by the filamentous fungus Aspergillus oryzae

Production of a novel Poria cocos immunomodulatory protein in Pichia pastoris: cloning, expression, purification and activities assays